
Peter D Gorycki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/653925/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Firstâ€inâ€Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2021, 10, 334-345.	1.6	1
2	Firstâ€inâ€Human Studies for a Selective RET Tyrosine Kinase Inhibitor, GSK3179106, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2019, 8, 234-245.	1.6	2
3	Investigation of Metabolism and Disposition of GSK1322322, a Peptidase Deformylase Inhibitor, in Healthy Humans Using the Entero-Test for Biliary Sampling. Drug Metabolism and Disposition, 2014, 42, 1314-1325.	3.3	8
4	Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. Xenobiotica, 2013, 43, 443-453.	1.1	69
5	Metabolism and Disposition of Oral Dabrafenib in Cancer Patients: Proposed Participation of Aryl Nitrogen in Carbon-Carbon Bond Cleavage via Decarboxylation following Enzymatic Oxidation. Drug Metabolism and Disposition, 2013, 41, 2215-2224.	3.3	41
6	Investigations of Hydrazine Cleavage of Eltrombopag in Humans. Drug Metabolism and Disposition, 2011, 39, 1747-1754.	3.3	13
7	Metabolism of [¹⁴ C]GSK977779 in Rats and Its Implication with the Observed Covalent Binding. Drug Metabolism and Disposition, 2011, 39, 1620-1632.	3.3	10
8	Metabolism and Disposition of Eltrombopag, an Oral, Nonpeptide Thrombopoietin Receptor Agonist, in Healthy Human Subjects. Drug Metabolism and Disposition, 2011, 39, 1734-1746.	3.3	40
9	Comparison of N,N′-diarylsquaramides and N,N′-diarylureas as antagonists of the CXCR2 chemokine receptor. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 1713-1717.	2.2	37
10	Discovery of potent and orally bioavailable N,N′-diarylurea antagonists for the CXCR2 chemokine receptor. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 4375-4378.	2.2	40
11	Present status of the application of cryopreserved hepatocytes in the evaluation of xenobiotics: consensus of an international expert panel. Chemico-Biological Interactions, 1999, 121, 117-123.	4.0	137
12	Pyrimidinylimidazole inhibitors of CSBP/P38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorganic and Medicinal Chemistry Letters, 1998, 8, 3111-3116.	2.2	132
13	The Oxidation of Tetrasubstituted Alkenes by Cytochrome P450. Chemical Research in Toxicology, 1994, 7, 745-751.	3.3	4
14	Phosphorus-32-postlabeling analysis of DNA adduction in mouse skin following topical administration of (+)-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene. Chemical Research in Toxicology, 1992, 5, 26-33.	3.3	11
15	Structure-activity relationships for the inhibition of DNA polymerase α by aphidicolln derivatives. Nucleic Acids Research, 1989, 17, 6339-6348.	14.5	12
16	Inhibition of topoisomerases by fredericamycin A. Cancer Chemotherapy and Pharmacology, 1989, 24, 167-171.	2.3	28